SECOND-LINE THERAPY WITH TOPOTECAN AND PEGYLATED LIPOSOMAL DOXORUBICIN VS. TOPOTECAN ALONE IN PATIENTS WITH RECURRENT OVARIAN CANCER

2003 ◽  
Vol 13 (Suppl 1) ◽  
pp. 53.4-53 ◽  
Author(s):  
P. L. Cherchi ◽  
G. Capobianco ◽  
F. Fattorini ◽  
A. M. Canetto ◽  
L. Milia ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Recurrent Ovarian Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma

Cancer ◽  
2008 ◽  
Vol 112 (5) ◽  
pp. 1147-1152 ◽  
Author(s):  
Giuseppe Di Lorenzo ◽  
Rossella Di Trolio ◽  
Vincenzo Montesarchio ◽  
Giovanna Palmieri ◽  
Paola Nappa ◽  
...  
Keyword(s):  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Kaposi Sarcoma ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Classic Kaposi Sarcoma

Timing for starting second-line therapy in recurrent ovarian cancer

2011 ◽  
Vol 11 (1) ◽  
pp. 49-55 ◽  
Author(s):  
Valentina Guarneri ◽  
Elena Barbieri ◽  
Maria Vittoria Dieci ◽  
Federico Piacentini ◽  
PierFranco Conte
Keyword(s):  
Ovarian Cancer ◽  
Recurrent Ovarian Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Altretamine for recurrent ovarian cancer or as maintenance after response to second-line therapy.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e15589-e15589 ◽  
Author(s):  
C. Mendiola ◽  
N. Valdiviezo ◽  
E. Vega ◽  
A. Sanchez Munoz ◽  
E. M. Ciruelos ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Recurrent Ovarian Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study

2019 ◽  
Vol 29 (1) ◽  
pp. 153-157 ◽  
Author(s):  
Elisa Tripodi ◽  
Gennaro Cormio ◽  
Ugo De Giorgi ◽  
Giorgio Valabrega ◽  
Daniela Rubino ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Liposomal Doxorubicin ◽  
Objective Response ◽  
Pegylated Liposomal Doxorubicin ◽  
Complete Response ◽  
Recurrent Ovarian Cancer ◽  
Hematological Toxicity ◽  
Cancer Relapse ◽  
Platinum Agent

BackgroundPegylated liposomal doxorubicin (PLD) is an active and well-tolerable treatment in ovarian cancer relapse, either alone or in combination with other drugs. No data are available on the possibility to rechallenge PLD treatment in long survivor patients with recurrent ovarian cancer, as evaluated for platinum agent, paclitaxel and gemcitabine. The aim of the present study was to evaluate the anti-tumor activity and the toxicity profile of re-challenge of PLD in recurrent ovarian cancer patients.MethodsData on 27 patients with epithelial ovarian cancer treated in the last ten years (2007-2017) with palliative PLD rechallenge were included in this multicenter retrospective Italian study.ResultsThe objective response rate to PLD re-treatment were complete response in 19%, partial response in 30% and stable disease in 37%. Only 1 case of G4 hematological toxicity was reported. No patient experienced severe cardiac impairment (G2-4).ConclusionPLD rechallenge represents an active and safe possibility of treatment for long survivor ovarian cancer patients.

Sign in / Sign up

Export Citation Format

Share Document